20 Oct

Biogen Stock: Performance in 3Q17

WRITTEN BY Mike Benson

A look at Biogen

Headquartered in Cambridge, Massachusetts, Biogen (BIIB) is a biopharmaceutical company. It discovers, develops, and manufactures drugs for various therapeutic areas, including immunology, neurology, oncology, and rare diseases.

Biogen Stock: Performance in 3Q17

The above chart shows revenues and EPS (earnings per share) over the last eight quarters and estimates for 3Q17.

Stock performance

Biogen stock has risen ~15.4% in 3Q17, while it has risen ~31.1% year-to-date as of October 20, 2017.

Analyst recommendations

Wall Street analysts estimate that the stock has the potential to rise ~1.0% over the next 12 months. Their recommendations show a 12-month target price of $345.79 per share compared to the last price of $342.42 per share as of October 19, 2017.

There are 29 analysts tracking Biogen stock. Twenty of them recommend a “buy,” and nine recommend a “hold.” None of them have recommended a “sell.” The consensus rating for Biogen stands at 2.07, which represents a “strong buy” for long-term growth investors and a “moderate buy” for momentum investors.

Analysts’ revenue estimates

Biogen’s revenues are mainly driven by strong sales of its neurology products as well as its immuno-oncology products.

Wall Street analysts estimate revenues of $3.0 billion in 3Q17, a ~2.8% rise compared to 3Q16, and EPS of $5.73.

To divest the company-specific risks, investors can consider ETFs such as the Health Care Select Sector SPDR ETF (XLV), which holds 2.2% of its total assets in Biogen (BIIB). XLV also holds 3.2% in Bristol-Myers Squibb (BMY), 2.5% in Eli Lilly (LLY), and 2.4% in Abbott Laboratories (ABT).

Latest articles

15 Jul

Will Amazon Prime Day 2019 Break 2018's Record?

WRITTEN BY Jitendra Parashar

This year, Amazon extended its Prime Day to 48 hours instead of the 36-hour sale in July 2018, making the 2019 event the longest Prime Day ever.

In a series of tweets on Monday, Trump today weighed in on China’s GDP growth, which came in at a 27-year low.

15 Jul

OrganiGram's Third-Quarter Earnings

WRITTEN BY Adam Jones

On Monday morning, OrganiGram's third-quarter earnings came in as a bit of a let-down. Here's why.

Trump is reportedly planning to increase the content of US-made steel in federal projects, which would be a lifeline for US steel companies.

Huawei is preparing for “extensive layoffs” in the US, which could put the US-China trade deal on the rocks.

With Q2's Netflix earnings just around the corner, here's what you can expect from the online streaming giant and the broader streaming space.